CD133 expression predicts post-operative recurrence in patients 
with colon cancer with peritoneal metastasis

Nagata,Hiroshi; Ishihara,Soichiro; Kishikawa,Junko; Sonoda,Hirofumi; Murono,Koji; Emoto,Shigenobu; Kaneko,Manabu; Sasaki,Kazuhito; Otani,Kensuke; Nishikawa,Takeshi; Tanaka,Toshiaki; Kiyomatsu,Tomomichi; Hata,Keisuke; Kawai,Kazushige; Nozawa,Hiroaki

doi:10.3892/ijo.2018.4240

CD133 expression predicts post-operative recurrence in patients with colon cancer with peritoneal metastasis

Authors:
- Hiroshi Nagata
- Soichiro Ishihara
- Junko Kishikawa
- Hirofumi Sonoda
- Koji Murono
- Shigenobu Emoto
- Manabu Kaneko
- Kazuhito Sasaki
- Kensuke Otani
- Takeshi Nishikawa
- Toshiaki Tanaka
- Tomomichi Kiyomatsu
- Keisuke Hata
- Kazushige Kawai
- Hiroaki Nozawa
View Affiliations

Affiliations: Department of Surgical Oncology, The University of Tokyo, Bunkyo-ku, Tokyo 113-8655, Japan, Department of Surgery, International University of Health and Welfare Sanno Hospital, Minato-ku, Tokyo 107-0052, Japan, Department of Surgery, Tohto Bunkyo Hospital, Bunkyo-ku, Tokyo 113-0034, Japan
Published online on: January 8, 2018 https://doi.org/10.3892/ijo.2018.4240
Pages: 721-732
Copyright: © Nagata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite extensive research on cancer stem cells in colorectal cancer, the impact of stem cell markers on patient survival remains unclear, particularly in those with distant metastasis. In this study, we focused on colon cancer with peritoneal metastasis and investigated the association between the expression of CD133, aldehyde dehydrogenase-1 (ALDH1) and leucine-rich repeating G-protein coupled receptor-5 (Lgr5), and disease prognosis. Putative stem cell marker expression was immunohistochemically evaluated in samples from 142 primary tumours and 75 peritoneal nodules. The associations between the expression of these markers and clinicopathological characteristics, overall survival and disease-free survival were analysed. The expression of CD133, ALDH1 and Lgr5 was found to be positive in 55.6, 47.2 and 78.9% of the primary tumour samples, respectively. While their expression was not associated with overall survival, disease-free survival was significantly worse in the CD133‑negative group (36.1 vs. 13.7%, P=0.041). Multivariable analysis confirmed that a negative CD133 expression was an independent risk factor for a reduced disease-free survival (P=0.005). Furthermore, the benefit of systemic chemotherapy was significantly greater in the CD133-negative group (P=0.039). On the whole, our data indicated that patients with colon cancer with CD133-negative expression had a reduced disease-free survival. Thus, we propose that CD133 expression may be a useful clinical biomarker in the treatment of colon cancer with peritoneal metastasis.

View Figures

View References

1	Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, et al Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. Mar 27–2017.Epub ahead of print. View Article : Google Scholar
2	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
3	Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD and Rafferty JF; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons: Practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. Dis Colon Rectum. 58:713–725. 2015. View Article : Google Scholar : PubMed/NCBI
4	Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, et al: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 27:1386–1422. 2016. View Article : Google Scholar : PubMed/NCBI
5	Vermeulen L, de Sousa e Melo F, Richel DJ and Medema JP: The developing cancer stem-cell model: Clinical challenges and opportunities. Lancet Oncol. 13:e83–e89. 2012. View Article : Google Scholar : PubMed/NCBI
6	Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL and Wahl GM: Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66:9339–9344. 2006. View Article : Google Scholar : PubMed/NCBI
7	Kishikawa J, Kazama S, Oba K, Hasegawa K, Anzai H, Harada Y, Abe H, Matsusaka K, Hongo K, Oba M, et al: CD133 Expression at the metastatic site predicts patients’ outcome in colorectal cancer with synchronous liver metastasis. Ann Surg Oncol. 23:1916–1923. 2016. View Article : Google Scholar : PubMed/NCBI
8	Yamamoto S, Tanaka K, Takeda K, Akiyama H, Ichikawa Y, Nagashima Y and Endo I: Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy. Ann Surg Oncol. 21:1853–1861. 2014. View Article : Google Scholar : PubMed/NCBI
9	Pitule P, Cedikova M, Daum O, Vojtisek J, Vycital O, Hosek P, Treska V, Hes O, Kralickova M and Liska V: Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients. BioMed Res Int. 2014:4321392014. View Article : Google Scholar : PubMed/NCBI
10	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell; West Sussex: 2010
11	Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T and Takao S: CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 98:1389–1397. 2008. View Article : Google Scholar : PubMed/NCBI
12	Saigusa S, Inoue Y, Tanaka K, Toiyama Y, Matsushita K, Kawamura M, Okugawa Y, Hiro J, Uchida K, Mohri Y, et al: Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 41:1643–1652. 2012. View Article : Google Scholar : PubMed/NCBI
13	Collett D: Modelling Survival Data in Medical Research. 3rd. CRC Press; London: 2015
14	Chen S, Song X, Chen Z, Li X, Li M, Liu H and Li J: CD133 expression and the prognosis of colorectal cancer: A systematic review and meta-analysis. PLoS One. 8:e563802013. View Article : Google Scholar : PubMed/NCBI
15	Zhao Y, Peng J, Zhang E, Jiang N, Li J, Zhang Q, Zhang X and Niu Y: CD133 expression may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer stem cell hypothesis: A meta-analysis. Oncotarget. 7:10023–10036. 2016.PubMed/NCBI
16	Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T and Jung A: The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol. 219:427–434. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kemper K, Versloot M, Cameron K, Colak S, de Sousa e Melo F, de Jong JH, Bleackley J, Vermeulen L, Versteeg R, Koster J, et al: Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer. Clin Cancer Res. 18:3132–3141. 2012. View Article : Google Scholar : PubMed/NCBI
18	Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et al: CD133 expression is not restricted to stem cells, and both CD133⁺ and CD133⁻ metastatic colon cancer cells initiate tumors. J Clin Invest. 118:2111–2120. 2008.PubMed/NCBI
19	Hongo K, Tanaka J, Tsuno NH, Kawai K, Nishikawa T, Shuno Y, Sasaki K, Kaneko M, Hiyoshi M, Sunami E, et al: CD133(−) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling. J Surg Res. 175:278–288. 2012. View Article : Google Scholar
20	Horst D, Kriegl L, Engel J, Kirchner T and Jung A: CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 99:1285–1289. 2008. View Article : Google Scholar : PubMed/NCBI
21	Ueno H, Murphy J, Jass JR, Mochizuki H and Talbot IC: Tumour ‘budding’ as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology. 40:127–132. 2002. View Article : Google Scholar : PubMed/NCBI
22	Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R and Salto-Tellez M: CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 23:450–457. 2010. View Article : Google Scholar : PubMed/NCBI
23	Stanisavljević L, Myklebust MP, Leh S and Dahl O: LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Acta Oncol. 55:1425–1433. 2016. View Article : Google Scholar
24	Sluiter N, de Cuba E, Kwakman R, Kazemier G, Meijer G and Te Velde EA: Adhesion molecules in peritoneal dissemination: Function, prognostic relevance and therapeutic options. Clin Exp Metastasis. 33:401–416. 2016. View Article : Google Scholar : PubMed/NCBI
25	Chen J, Xia Q, Jiang B, Chang W, Yuan W, Ma Z, Liu Z and Shu X: Prognostic value of cancer stem cell marker ALDH1 expression in colorectal cancer: A systematic review and meta-analysis. PLoS One. 10:e01451642015. View Article : Google Scholar : PubMed/NCBI
26	Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G and Zoetmulder FA: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 12:65–71. 2005. View Article : Google Scholar : PubMed/NCBI
27	Nagata H, Ishihara S, Hata K, Murono K, Kaneko M, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, et al: Survival and prognostic factors for metachronous peritoneal metastasis in patients with colon cancer. Ann Surg Oncol. 24:1269–1280. 2017. View Article : Google Scholar